We partner with our sister company, Neurovations Clinical Research, to offer our patients access to advanced new trial therapies for Chronic Pain.

Neurovations is focused on new and innovative clinical trials and treatments for chronic pain and neurologic disease. Founded by Eric Grigsby, MD, MBA, long-time leader in pain management, Neurovations enjoys a reputation for excellence decades in the making. Our team has led clinical trials for more than 25 companies in the fields of pain management and minimally invasive spine care, partnering with industry leaders and early-stage companies in medical device (Phase I-IV) and pharmaceutical trials (Phase II-IV).

Neurovations Lumbar Disc Herniation Study

We are enrolling patients in a new clinical study for lumbar disc herniation to evaluate a very unique injection treatment. In this study, a tiny amount of an enzyme is placed in the herniated disc, which may help reduce symptoms associated with lumbar disc herniation.

If you have inadequate pain relief from simpler treatments for a lumbar disc herniation, please reach out to us in Napa at Neurovations Research. We are the region’s most experienced clinical research facility for pain.

If accepted for this study, you will receive free study-related medical care. To see if you qualify, call Neurovations at 707-252-9606 or click on the link below to email us.

Have you started noticing changes in your memory or ability to think clearly?

If you are noticing changes in your memory or ability to think clearly, you may pre-qualify for a clinical research study for early symptomatic Alzheimer’s disease. This study will look at whether an investigational drug works and how safe it is in people with early symptomatic Alzheimer’s disease. The study will involve people who have memory loss that has gotten worse over time.

To see if you qualify, call Neurovations at 707-252-9606 or click on the link below to email us.

What is the cost?

All study related care will be provided at no cost to you.  Health insurance is not required and your time and travel will be compensated.

In order to qualify, you must:

• Be 60 to 85 years old

• Have memory loss that has gotten worse over time

• Have a study partner who knows you and is willing to attend appointments with you throughout the study

How does it work?

For people with Alzheimer’s disease, an unwanted substance called “beta-amyloid” (or “β-amyloid”) builds up and forms plaques in the brain. It is believed that the build-up of β-amyloid plaques disrupts how brain cells function and leads to cell death. This study will examine whether an investigational drug, donanemab, can target and remove β-amyloid plaques. It is hoped that this can slow or stop the progress of Alzheimer’s by targeting and removing amyloid plaques.

To see if you qualify, call Neurovations at 707-252-9606 or click on the link below to email us.

Email Neurovations Research to Learn More